Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
Clinical trial NCT00126893 · TERMINATED
Trial details
- NCT number
- NCT00126893
- Sponsor
- Celgene Corporation
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2005-10-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.